Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Kazuya Konishi, Jun Araya, Makoto Nagabuchi, Takashi Sakamoto, Jiro Ogino, Satoshi Hirano
Metaplastic carcinoma is a rare histological malignancy, often triple-negative, and has a poor prognosis. Here, we report a case of breast cancer in which the primary lesion degenerated into squamous cell carcinoma(triple negative)after drug treatment for invasive ductal carcinoma(Luminal type). The patient was a 41-year-old woman who was diagnosed with Stage Ⅳ left breast cancer T2N2bM1(HEP)(ER 90%, PR 70%, HER2 2+, FISH-)at another hospital and participated in the PATHWAY study(tamoxifen plus goserelin plus palbociclib/placebo)...
July 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
#22
JOURNAL ARTICLE
Satoru Taguchi, Mizuki Onozawa, Shiro Hinotsu, Taketo Kawai, Takeshi Mitomi, Satoshi Uno, Haruki Kume
OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among patients in the Japan Study Group of Prostate Cancer registry, those who initiated primary androgen deprivation therapy and were aged 20 years or older were enrolled in this study...
July 5, 2023: Japanese Journal of Clinical Oncology
#23
JOURNAL ARTICLE
Zsuzsanna Kovács, Fiona Reidy, Louise Glover, Fionnuala M McAuliffe, Henning Stockmann, Mark T Kilbane, Patrick J Twomey, Maire Peters, Merli Saare, Pauline M Rudd, Meeme Utt, Mary Wingfield, Andres Salumets, Radka Saldova
Endometriosis is a chronic inflammatory gynaecological disease characterized by the growth of endometrial tissue outside the uterine cavity. There are currently no definitive non-invasive diagnostic tools. Glycosylation is the most common posttranslational modification of proteins and altered glycosylation has been found in many diseases, including chronic inflammatory conditions and cancer. Sialylation and galactosylation on serum IgG have previously been found to be altered in endometriosis and serum sialylation changed after Zoladex (Goserelin Acetate) therapy...
June 28, 2023: Scientific Reports
#24
REVIEW
Xu Yang, Lin Yang
Premature ovarian failure (POF) is an insidious cause of female infertility and a devastating condition for women. POF also has a strong familial and heterogeneous genetic background. Management of POF is complicated by the variable etiology and presentation, which are generally characterized by abnormal hormone levels, gene instability and ovarian dysgenesis. To date, abnormal regulation associated with POF has been found in a small number of genes, including autosomal and sex chromosomal genes in folliculogenesis, granulosa cells, and oocytes...
2023: Frontiers in Medicine
#25
JOURNAL ARTICLE
Mariana Molina-Jaimes, Antonio Galindo-González, Haydeé Cristina Verduzco-Aguirre, Sergio Bautista-Arredondo, Gustavo Reyes-Terán, Enrique Soto-Perez-de-Celis
PURPOSE: To estimate the cost-effectiveness of adding a CDK4/6 inhibitor to standard endocrine therapy in the first-line setting for advanced HR+/HER2- breast cancer in postmenopausal and premenopausal women, from the perspective of the Mexican public healthcare system. METHODS: We used a partitioned survival model to simulate relevant health outcomes in a synthetic cohort of patients with breast cancer derived from the PALOMA-2, MONALEESA-2, MONARCH-3 trials for postmenopausal patients, and from the MONALEESA-7 study for premenopausal patients...
June 17, 2023: Clinical & Translational Oncology
#26
JOURNAL ARTICLE
Long Yang, Wen Huang, Xiaoyu Bai, Haoyu Wang, Xiaolei Wang, Huiyuan Xiao, Yanlei Li
The incidence of bladder cancer (BLCA) in men is higher than that in women. Differences in androgen levels between men and women are considered the main causes of incidence rate differences. In this study, dihydrotestosterone (DHT) significantly increased the proliferation and invasion of BLCA cells. In addition, BLCA formation and metastatic rates were higher in N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-treated male mice than in female and castrated male mice in vivo. However, immunohistochemistry showed that androgen receptor (AR) was expressed at low levels in normal and BLCA tissues of men and women...
June 16, 2023: Cell Death & Disease
#27
JOURNAL ARTICLE
Dennis J Slamon, Peter A Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H Barrios, Aditya Bardia, Seock-Ah Im, Denise A Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N Hortobagyi
BACKGROUND: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. New Adjuvant Trial with Ribociclib [LEE011] (NATALEE) is a trial evaluating the efficacy and safety of adjuvant ribociclib plus endocrine therapy (ET) versus ET alone in patients with HR+/HER2- early nonmetastatic breast cancer (EBC). METHODS/DESIGN: NATALEE is a multicenter, randomized, open-label, Phase III trial in patients with HR+/HER2- EBC...
2023: Therapeutic Advances in Medical Oncology
#28
Cristina Marinela Oprean, Andrei Dorin Ciocoiu, Nusa Alina Segarceanu, Diana Moldoveanu, Alexandra Stan, Teodora Hoinoiu, Ioana Chiorean-Cojocaru, Daciana Grujic, Adelina Stefanut, Daniel Pit, Alis Dema
Breast cancer is the most frequent neoplasm among women and the second leading cause of death by cancer. It is the most frequent cancer diagnosed during pregnancy. Pregnancy-associated breast cancer is defined as breast cancer that is diagnosed during pregnancy and/or in the postpartum period. Data about young women with metastatic HER2-positive cancer who desire a pregnancy are scarce. The medical attitude in these clinical situations is difficult and nonstandardized. We present the case of a 31-year-old premenopausal woman diagnosed in December 2016 with a stage IV Luminal HER2-positive metastatic breast cancer (pT2 N0 M1 hep)...
May 8, 2023: Current Oncology
#29
JOURNAL ARTICLE
Alexandre Luiz Korte de Azevedo, Tamyres Mingorance Carvalho, Cristiane Sato Mara, Igor Samesima Giner, Jaqueline Carvalho de Oliveira, Daniela Fiori Gradia, Iglenir João Cavalli, Enilze M S F Ribeiro
Metastasis is a multi-step process that leads to the dissemination of tumor cells to new sites and, consequently, to multi-organ neoplasia. Although most lethal breast cancer cases are related to metastasis occurrence, little is known about the dysregulation of each step, and clinicians still lack reliable therapeutic targets for metastasis impairment. To fill these gaps, we constructed and analyzed gene regulatory networks for each metastasis step (cell adhesion loss, epithelial-to-mesenchymal transition, and angiogenesis)...
May 22, 2023: Functional & Integrative Genomics
#30
RANDOMIZED CONTROLLED TRIAL
Sunita Sharma, Sourav RoyChoudhury, M Padmaja Bhattacharya, Shubhendu Hazra, Arup Kumar Majhi, Kamal C Oswal, Ratna Chattopadhyay
RESEARCH QUESTION: Can low-dose letrozole reduce dysmenorrhoea, menorrhagia and sonographic features in symptomatic women with adenomyosis awaiting IVF? DESIGN: This was a longitudinal randomized prospective pilot study to explore the effectiveness of low-dose letrozole and compare it with a gonadotropin releasing hormone (GnRH) agonist in reducing dysmenorrhoea, menorrhagia and sonographic features in symptomatic women with adenomyosis awaiting IVF. The women were treated for 3 months, either with the GnRH agonist goserelin 3...
July 2023: Reproductive Biomedicine Online
#31
Fanyu Meng, Rong Su, Li Ling, Weitian Yan, Shiyu Du, Jiangyun Peng, Weichao Liu
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, and precocious puberty. The side effects of the drug include allergic rash, flushing, excessive sweating, skin swelling at the injection site, sexual dysfunction, erectile dysfunction, and menopausal symptoms. However, erythema nodosum has so far not been reported. In this paper, we have presented the case of erythema nodosum caused by goserelin acetate and a review of the literature on its adverse effects, thus providing useful insights into clinical management and medication safety...
April 28, 2023: International Journal of Rheumatic Diseases
#32
REVIEW
Paolo Vercellini, Veronica Bandini, Laura Buggio, Giussy Barbara, Nicola Berlanda, Dhouha Dridi, Maria Pina Frattaruolo, Edgardo Somigliana
STUDY QUESTION: Is it possible to reduce the cost of GnRH agonist treatment for endometriosis by using non-standard dosing regimens? SUMMARY ANSWER: An extended-interval dosing regimen of a 3.75 mg depot formulation of triptorelin injected every 6 weeks instead of every 4 weeks reduces the cost by one-third without compromising the effect on pain relief. WHAT IS KNOWN ALREADY: Cost constitutes a limit to prolonged GnRH agonists use...
2023: Human Reproduction Open
#33
JOURNAL ARTICLE
Chengyuan Gu, Zengjun Wang, Tianxin Lin, Zhiyu Liu, Weiqing Han, Xuhui Zhang, Chao Liang, Hao Liu, Yang Yu, Zhenzhou Xu, Shuang Liu, Jingen Wang, Linghua Jia, Xin Yao, Wenfeng Liao, Cheng Fu, Zhaohui Tan, Guohua He, Guoxi Zhu, Rui Fan, Wenzeng Yang, Xin Chen, Zhizhong Liu, Liqiang Zhong, Benkang Shi, Degang Ding, Shubo Chen, Junli Wei, Xudong Yao, Ming Chen, Zhanpeng Lu, Qun Xie, Zhiquan Hu, Yinhuai Wang, Hongqian Guo, Tiwu Fan, Zhaozhao Liang, Peng Chen, Wei Wang, Tao Xu, Chunsheng Li, Jinchun Xing, Hong Liao, Dalin He, Zhibin Wu, Jiandi Yu, Zhongwen Feng, Mengxiang Yang, Qifeng Dou, Quan Zeng, Yuanwei Li, Xin Gou, Guangchen Zhou, Xiaofeng Wang, Rujian Zhu, Zhonghua Zhang, Bo Zhang, Wanlong Tan, Xueling Qu, Hongliang Sun, Tianyi Gan, Dingwei Ye
BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections...
April 3, 2023: Chinese Medical Journal
#34
JOURNAL ARTICLE
Zhijun Hu, Kaijiang Liu, Qing Liu, Hong Zhu
A woman in her early 20s presented with cough and fever. She had undergone an abdominal myomectomy 3 years ago for uterine leiomyoma. Chest CT and positron emission tomography-CT revealed multiple round nodules in both lungs, suggesting metastatic lesions. A CT-guided lung biopsy was performed, and the tumour was diagnosed as pulmonary benign metastasising leiomyoma (PBML) based on pathological analyses. Whole exon capture sequencing of uterine leiomyoma and PBML sections revealed that 13 genes (MCM10, SLC16A9, RAG1, BAZ1A, NLRP2, TRMT61B, CPXM1, NGLY1, SUCLG2, FAM13A, CAGE1, PHTF2 and ZDHHC2) were concurrently present in the two tumours...
March 22, 2023: BMJ Case Reports
#35
Ana Valente, Nuno Teixeira Tavares, Cláudia Caeiro, Miguel Barbosa, Isabel Augusto
A small but important subset of patients with metastatic breast cancer has an oligometastatic disease. Some of these patients are highly responsive to systemic therapy and have the potential to achieve complete remission with treatment. However, it remains to be clarified the best locoregional and systemic treatment strategy for such patients and what features can determine whose patients are the best candidates. We also don't know what will be the role of cyclin-dependent kinase 4/6 inhibitors in those cases...
February 2023: Curēus
#36
JOURNAL ARTICLE
Mao Yutong, Ye Liang, Sha Chunjie, Guan Xiaolin, Gong Xiaoyan, Dong Lin, Du Guangying, Zhang Xuemei, Cen Xiaobo, Tian Jingwei, Yu Pengfei, Wang Hongbo
LY01005 is an investigational new drug product of goserelin acetate which is formulated as extended-release microspheres for intramuscular injection. To support the proposed clinical trials and marketing application of LY01005, pharmacodynamics, pharmacokinetics and toxicity studies were performed in rats. In the pharmacological study in rats, LY01005 induced an initial supra-physiological level increase of testosterone at 24 h post-dosing which then rapidly fell to castration level. The potency of LY01005 was comparable to the comparator Zoladex® but its effect lasted longer and more stable...
2023: Frontiers in Pharmacology
#37
Manuel Rösch, Christian Bieg, Spasenija Savic, Martin Buess
Salivary duct carcinoma (SDC) is a rare subtype of salivary cancers associated with androgen receptor and human epidermal growth factor receptor 2 (HER2/neu) overexpression. It shows a high propensity to give rise to distant metastases mainly to the lung, the bone, and the liver. Intracranial metastases are rare. We report the case of a 61-year-old male patient with SDC developing intracranial metastases. Unresponsive to radiotherapy and anti-HER/neu targeted therapy the intracranial metastases showed a very good partial remission to androgen deprivation therapy with goserelin acetate...
2023: Case Reports in Oncology
#38
JOURNAL ARTICLE
Yangyang Liu, Zhihong Dai, Jiange Hao, Liang Wang, Zhiyu Liu
Cervical lymphadenopathy as the initial presentation of metastatic prostate cancer is particularly uncommon, and easily misdiagnosed. In the current study, we describe five cases of metastatic prostate cancer in our hospital that presented with cervical lymphadenopathy as an initial symptom. The diagnosis was confirmed by needle biopsy of the suspicious lymph nodes and the serum prostate specific antigen (PSA) levels of all patients exceeded 100 ng/ml. The five patients were treated with hormonal therapy; four received traditional hormonal therapy, including bicalutamide and goserelin; one patient received hormonal therapy that included abiraterone and goserelin...
2023: Frontiers in Surgery
#39
JOURNAL ARTICLE
Sung Eun Kim, Won-Ji Kim, DooSeok Choi, Dong-Yun Lee
PURPOSE: Although different gonadotropin-releasing hormone (GnRH) agonists may have different effects, their effect of ovarian protection during chemotherapy for breast cancer has not been compared. This study aimed to compare the effects of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer. METHODS: This prospective study analyzed 193 patients with breast cancer aged ≤ 40 years who had regular menstruation and serum anti-Müllerian hormone (AMH) levels ≥ 1 ng/mL before treatment...
April 2023: Breast Cancer Research and Treatment
#40
JOURNAL ARTICLE
K Alsaleh, H Al Zahwahry, A Bounedjar, M Oukkal, A Saadeddine, H Mahfouf, K Bouzid, A Bensalem, T Filali, H Abdel-Razeq, B Larbaoui, A Kandil, O Abulkhair, M Al Foheidi, M Ghosn, H Rasool, H Boussen, A Mezlini, A Haddaoui, J Ayari, M Al Ghamdi, H Errihani, N Abdel-Aziz, M Arafah, F Dabouz, M Bahadoor, S Kullab, J M Nabholtz
BACKGROUND: The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new startegies. OBJECTIVE: Analyze the complete pathologic response (pCR) rate and overall response in a low-risk hormone-positive subset of patients receiving neoadjuvant hormone treatment (NAHT) with or without Palbociclib (a CDK4/CDK6 inhibitor) to boost NAHT effectiveness...
January 21, 2023: Journal of Cancer Research and Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
